• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Gemcitabin “Ebewe” 40 mg/ml
    / Pharmalogic


    Active Ingredient
    Gemcitabine (HCl) 4 mg/ml

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Vial

    5 ml x 200 mg

    partial basket chart 3559 7861

    Vial

    25 ml x 1000 mg

    partial basket chart 3560 7862

    Vial

    50 ml x 2000 mg

    partial basket chart 3561 7863

    Related information


    Dosage

    According to indication.
    See prescribing information for full details.


    Indications

    Palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-FU refractory pancreatic cancer.Treatment of patients with bladder cancer at the invasive stage.In combination with paclitaxel for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated.In combination with carboplatin for the treatment of patients with recurrent epithelial ovarian carcinoma that has relapsed at least six months after platinum based therapy.


    Contra-Indications

    Hypersensitivity to gemcitabine, or to any of the constituents. Pregnancy, lactation.
    See prescribing information for full details.


    Special Precautions

    See prescribing information for full details.


    Side Effects

    Nausea with or without vomiting, raised AST/ALT and alkaline phosphotases. Proteinuria and hematuria, dyspnea, allergic skin rashes.
    See prescribing information for full details.


    Drug interactions

    See prescribing information for full details.


    Manufacturer
    Ebewe Pharma
    Licence holder
    CLOSE